Albumin Market By Product Type (Human Albumin, Bovine Serum Albumin (BSA), Recombinant Albumin), By Application (Therapeutic Uses, Diagnostic Applications, Research and Laboratory Uses, Industrial Uses), By End-User Industry (Hospitals and Clinics, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biopharmaceutical Companies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Albumin Market was valued at USD 5.6 billion in 2023 and will surpass USD 9.5 billion by 2030; growing at a CAGR of 7.9% during 2024 - 2030.

The albumin market is witnessing significant growth due to the increasing demand for albumin-based products across therapeutic, diagnostic, and research applications. Albumin, a vital protein found in blood plasma, plays a crucial role in various medical treatments and clinical applications, including volume replacement therapies, liver disease management, and diagnostic assays. The market for albumin products has evolved with the advancements in biotechnology, leading to the development of more efficient and cost-effective production methods, including recombinant albumin. As a result, albumin-based therapies have gained widespread use across hospitals, clinics, research institutes, and diagnostic laboratories, contributing to the expansion of the global albumin market.

Driven by the growing need for plasma-derived and recombinant proteins in the treatment of chronic diseases, burns, and liver disorders, the albumin market is expected to continue expanding. Additionally, emerging applications in diagnostics and the increasing adoption of biopharmaceuticals further propel this growth. Below, we explore some of the largest and fastest-growing subsegments within each segment of the market.

Human Albumin Segment Is Largest Owing to Broad Therapeutic Applications

The human albumin segment holds the largest share in the global albumin market, primarily due to its widespread therapeutic use in critical care settings. Human albumin is commonly used for plasma volume expansion, managing burns, liver disease, and shock, among other medical conditions. This product is highly preferred for therapeutic applications, as it helps to maintain blood pressure, fluid balance, and provide nourishment to patients. The demand for human albumin is further driven by the rising number of patients suffering from chronic conditions, the global aging population, and the increasing incidence of trauma and surgical interventions that require albumin-based therapy.

Human albumin remains the standard for several life-saving treatments due to its biocompatibility and established safety profile. Given its broad range of applications in the hospital and critical care environments, human albumin is the most used form in the albumin market, cementing its position as the largest subsegment. As the global healthcare burden increases, particularly in developing regions with less access to alternative treatments, the demand for human albumin is anticipated to continue rising, securing its dominant role in the market.

Therapeutic Uses Segment Is Largest Owing to High Demand in Critical Care

The therapeutic uses segment is the largest in the albumin market, driven by the increasing demand for albumin-based therapies in critical care settings. Human albumin is an essential component in treating various medical conditions such as burns, shock, hypoalbuminemia, liver disease, and during surgeries or trauma care. It is widely administered for plasma volume replacement, helping to restore proper circulation and prevent organ failure in critically ill patients. The therapeutic uses of albumin are particularly prominent in hospital emergency departments, intensive care units (ICUs), and trauma centers.

The continuous rise in patients with chronic diseases, particularly those requiring frequent blood transfusions or surgeries, supports the growth of the therapeutic uses segment. The expansion of healthcare infrastructure in both developed and emerging markets further accelerates the demand for human albumin in hospitals and clinics. As healthcare systems worldwide continue to focus on improving patient outcomes, the therapeutic use of albumin-based products is expected to maintain its leading position in the market.

Biopharmaceutical Companies Segment Is Fastest Growing Owing to Increased Use in Drug Development

The biopharmaceutical companies segment is the fastest-growing subsegment within the albumin market, primarily due to the increasing application of albumin in the development and production of biologic drugs. Biopharmaceutical companies use albumin as a stabilizing agent in protein formulations, as it helps maintain the integrity of biologic drugs and prolongs their shelf life. Recombinant albumin, in particular, is being incorporated into novel drug formulations to improve efficacy and reduce side effects, driving significant growth in this sector.

As biopharmaceutical companies continue to explore new therapeutic solutions for chronic diseases, cancer, and autoimmune disorders, the use of albumin in drug development has become more prevalent. The adoption of albumin as a stabilizer in drug formulations not only enhances drug performance but also reduces manufacturing costs, making it an attractive option for pharmaceutical companies. The increasing trend towards biologics, coupled with the rise of personalized medicine, is expected to accelerate the growth of the biopharmaceutical companies segment, positioning it as the fastest-growing subsegment within the albumin market.

North America Region Is Largest Owing to Strong Healthcare Infrastructure and High Demand

North America dominates the albumin market, driven by its well-established healthcare infrastructure, high adoption rates of albumin-based therapies, and a large population of patients requiring critical care. The United States, in particular, holds a significant share of the market due to the prevalence of chronic diseases, such as liver cirrhosis, burn injuries, and cancer, which require albumin therapy. Additionally, the presence of leading pharmaceutical and biopharmaceutical companies in the region has contributed to the rapid development and availability of albumin-based products.

North America’s dominance is also fueled by advancements in medical research, regulatory support for albumin therapies, and a robust reimbursement system that supports the widespread use of albumin in hospitals and healthcare settings. As healthcare spending continues to increase and the aging population grows, North America is expected to maintain its leadership in the global albumin market. The region's ability to adopt cutting-edge healthcare technologies and innovations also positions it as a major player in the albumin market.

Competitive Landscape and Leading Companies

The albumin market is highly competitive, with numerous global and regional companies vying for market share. Leading companies in this market include Grifols, CSL Behring, Shire (Takeda Pharmaceutical Company), Octapharma, and Baxter International, among others. These companies dominate the market through extensive product portfolios, strong distribution networks, and continuous research and development initiatives focused on enhancing albumin-based therapies and developing new applications.

To maintain a competitive edge, these companies are focusing on expanding their production capacities, improving the efficiency of albumin manufacturing, and investing in recombinant albumin technologies. Mergers and acquisitions (M&A) are common in the market, as companies seek to enhance their product offerings and broaden their market reach. Additionally, regulatory approvals and strategic partnerships play a crucial role in the competitive dynamics of the albumin market. As the demand for albumin-based therapies continues to grow, the market is expected to see more collaborations and innovations aimed at improving patient outcomes and reducing treatment costs

Recent Developments:

• Grifols has announced the acquisition of Biotest AG, a global leader in blood plasma-based products, to expand its albumin offerings and strengthen its position in the global albumin market.
• CSL Behring has received approval from the U.S. FDA for a new albumin-based therapy, providing enhanced treatment options for patients with severe burns and liver failure.
• Fresenius Kabi introduced a new recombinant albumin product, aimed at providing an alternative to human-derived albumin for use in diagnostic and therapeutic applications.
• Takeda Pharmaceutical has expanded its albumin production facility in Japan, increasing its capacity to meet the growing demand for therapeutic albumin in Asia and other regions.
• Baxter International has acquired new albumin manufacturing technology to improve production efficiency and meet the rising global demand for human albumin for critical care treatments.

List of Leading Companies:

• Grifols
• CSL Behring
• Shire (Takeda Pharmaceutical Company)
• Octapharma
• Biotest AG
• Sichuan Yuanda Shuyang Pharmaceutical
• Eli Lilly and Company
• Fresenius Kabi
• Baxter International Inc.
• Sanofi
• AbbVie
• Emergent BioSolutions
• Shanghai RAAS Blood Products Co. Ltd.
• Jiangsu Kanion Pharmaceutical Co. Ltd.
• Hualan Biological Engineering

Report Scope: